Corvus Pharmaceuticals, Inc. Balance Sheet
CRVS / Health Care|11 years of annual SEC 10-K data (FY2014-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 11 fiscal years. All figures from audited SEC 10-K filings.
Corvus Pharmaceuticals, Inc. had $69M in total assets and $33M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.7M | $12.6M | $13.2M | $63.5M | $16.5M | $5.2M | $39.2M | $45.1M | $5.0M | $4.1M | $12.5M |
| Accounts Receivable | $75.0K | $26.0K | $588.0K | - | - | - | - | - | - | - | - |
| Current Assets | $54.4M | $28.0M | $43.7M | $71.3M | $45.3M | $79.3M | $115.6M | $91.2M | $136.0M | $95.7M | - |
| PP&E (Net) | $151.0K | $236.0K | $353.0K | $451.0K | $906.0K | $1.5M | $2.2M | $2.7M | $3.2M | $1.8M | - |
| Total Assets | $68.9M | $45.6M | $68.2M | $109.5M | $85.5M | $83.6M | $118.2M | $94.8M | $140.2M | $98.5M | - |
| Current Liabilities | $35.4M | $6.9M | $10.8M | $9.7M | $12.1M | $10.2M | $7.0M | $9.0M | $5.9M | $3.1M | - |
| Shareholders' Equity | $32.6M | $38.7M | $56.1M | $97.2M | $72.1M | $71.1M | $110.3M | $84.8M | $132.8M | -$31.1M | -$159.0K |